CBR3-AS1

Summary

CBR3-AS1 (CBR3 antisense RNA 1, HGNC:43664) is a long non-coding RNA gene on chromosome 21q22.12.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:43664
Approved symbol	CBR3-AS1
Name	CBR3 antisense RNA 1
Location	21q22.12
Locus type	RNA, long non-coding
Status	Approved
Aliases	PlncRNA-1
Ensembl gene	ENSG00000236830
Ensembl biotype	lncRNA
Entrez	100506428
RNAcentral	URS000075ACB3 — lncRNA, 1575 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 53 — 51 lncRNA, 2 retained_intron

ENST00000413862, ENST00000427491, ENST00000432988, ENST00000453159, ENST00000608622, ENST00000608632, ENST00000608641, ENST00000608690, ENST00000609192, ENST00000623484, ENST00000623579, ENST00000623638, ENST00000623647, ENST00000624080, ENST00000624086, ENST00000624883, ENST00000625079, ENST00000625189, ENST00000654957, ENST00000655785, ENST00000656513, ENST00000661388, ENST00000662189, ENST00000666303, ENST00000667457, ENST00000718361, ENST00000718362, ENST00000733812, ENST00000733813, ENST00000733814, ENST00000733815, ENST00000733816, ENST00000733817, ENST00000733818, ENST00000733819, ENST00000733820, ENST00000733821, ENST00000733822, ENST00000733823, ENST00000733824, ENST00000733825, ENST00000733826, ENST00000733827, ENST00000733828, ENST00000733829, ENST00000733830, ENST00000733831, ENST00000733832, ENST00000733833, ENST00000733834, ENST00000733835, ENST00000733836, ENST00000733837

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000413862 — 4 exons

Exon	Start	End
ENSE00001606093	36146256	36146355
ENSE00001646746	36156217	36156360
ENSE00001736440	36133687	36133761
ENSE00004065415	36131776	36133074

Expression profiles

Bgee: expression breadth ubiquitous, 167 present calls, max score 86.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.2401 / max 188.4355, expressed in 1147 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
190355	4.6921	906
190354	0.5480	320

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
minor salivary gland	UBERON:0001830	86.53	gold quality
lower esophagus mucosa	UBERON:0035834	85.79	gold quality
saliva-secreting gland	UBERON:0001044	85.33	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.40	gold quality
esophagus mucosa	UBERON:0002469	82.29	gold quality
mouth mucosa	UBERON:0003729	82.03	gold quality
prostate gland	UBERON:0002367	81.13	gold quality
sural nerve	UBERON:0015488	80.04	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	79.17	gold quality
left lobe of thyroid gland	UBERON:0001120	78.67	gold quality
mucosa of transverse colon	UBERON:0004991	78.67	gold quality
right lobe of thyroid gland	UBERON:0001119	78.29	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	78.00	silver quality
thyroid gland	UBERON:0002046	77.66	gold quality
body of stomach	UBERON:0001161	77.53	gold quality
islet of Langerhans	UBERON:0000006	77.52	gold quality
skin of abdomen	UBERON:0001416	77.50	gold quality
skin of leg	UBERON:0001511	77.50	gold quality
vagina	UBERON:0000996	77.40	gold quality
apex of heart	UBERON:0002098	77.11	gold quality
parotid gland	UBERON:0001831	76.78	gold quality
body of pancreas	UBERON:0001150	76.77	gold quality
transverse colon	UBERON:0001157	76.63	gold quality
rectum	UBERON:0001052	76.52	gold quality
esophagus	UBERON:0001043	76.44	gold quality
ectocervix	UBERON:0012249	75.91	gold quality
pancreas	UBERON:0001264	75.89	gold quality
hindlimb stylopod muscle	UBERON:0004252	75.53	gold quality
metanephros cortex	UBERON:0010533	75.44	gold quality
amniotic fluid	UBERON:0000173	75.08	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.56

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 21)

• PlncRNA-1 plays an important role in esophageal squamous cell carcinoma cell proliferation. Overexpression of PlncRNA-1 is correlated with advanced tumor stage and lymph node metastasis. (PMID:24337686)
• Functional analysis revealed that miR-34c and miR-297 overexpression down-regulated AR expression and inhibited the expression of downstream AR targets and that PlncRNA-1 overexpression rescued these effects. (PMID:26808578)
• PlncRNA-1 expression is up-regulated in human Hepatocellular Carcinoma tissues and correlated with tumor stage and metastasis. (PMID:26906068)
• Data suggest that long noncoding RNA PlncRNA1 and microRNA miR-34c bound together to regulate the expressions of MAZ, ZO-1 and occludin. (PMID:28153728)
• PlncRNA-1 is an oncogene that regulates the cell cycle, cyclin-D1 and EMT in prostate cancer cells through the TGF-beta1 pathway. (PMID:28212533)
• PlncRNA-1 knockdown remarkably reduced cell proliferation, migration, and invasion and promoted cell apoptosis in vitro. In vivo xenograft experiments showed that PlncRNA-1 inhibition significantly suppressed tumor growth. (PMID:28835319)
• In conclusion, PlncRNA-1 and TUG1 genes may play a critical role in gastric cancer (GC) progression and may serve as potential diagnostic biomarkers in GC patients (PMID:29182008)
• There was no association between LncRNA CBR3-AS1 (also known as PlncRNA-1), and CBR3 expression in osteosarcoma tissues. In conclusion, lncRNA CBR3-AS1 serves an independent poor prognostic factor for osteosarcoma patients. (PMID:29554595)
• LncRNA PlncRNA-1 overexpression inhibits the growth of breast cancer by upregulating TGF-beta1 and downregulating PHGDH. PlncRNA-1 was downregulated in primary breast tumor tissues comparing with adjacent healthy tissues. (PMID:29626321)
• These results suggest that the PlncRNA-1/miR-204/ Wnt/beta-catenin regulatory network may shed light on tumorigenesis in colorectal cancer. (PMID:29738066)
• patients with advanced stage retinoblastoma had higher levels of PlncRNA-1 expression than patients with early stage retinoblastoma. There was an inverse correlation between PlncRNA-1 expression and CBR3 expression in retinoblastoma tissues, and PlncRNA-1 negatively regulated mRNA and protein expressions of CBR3. (PMID:30096220)
• High expression of Plnc RNA-1 promotes the progression of colorectal cancer. (PMID:30941957)
• LncRNA PlncRNA-1 participates in rheumatoid arthritis by regulating transforming growth factor beta1. (PMID:32543888)
• Long noncoding RNA CBR3 antisense RNA 1 promotes the aggressive phenotypes of nonsmallcell lung cancer by sponging microRNA5093p and competitively upregulating HDAC9 expression. (PMID:32945466)
• Hypomethylation of PlncRNA-1 promoter enhances bladder cancer progression through the miR-136-5p/Smad3 axis. (PMID:33288752)
• LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway. (PMID:33494806)
• LncRNA PlncRNA-1 accelerates the progression of prostate cancer by regulating PTEN/Akt axis. (PMID:33848262)
• Long Non-Coding RNAs Expression in Breast Cancer: CBR3-AS1 LncRNA as a Sensitive Biomarker. (PMID:34582659)
• Long Non-coding RNA CBR3 Antisense RNA 1 is Downregulated in Colorectal Cancer and Inhibits miR-29a-Mediated Cell Migration and Invasion. (PMID:35107754)
• LncRNA CBR3-AS1 predicts a poor prognosis and promotes cervical cancer progression through the miR-3163/LASP1 pathway. (PMID:36591804)
• LncRNA-CBR3-AS1 promotes and enhances the malignancy of ulcerative colitis via targeting miRNA-145-5p/FN1. (PMID:37715388)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.